Prof. Dr. Rosanna di paola, università degli studi di messina, Italy
Prof. Dr. Rosanna Di Paola is a Full Professor of General Biochemistry at the University of Messina, Italy, specializing in clinical pathology and experimental medicine. She holds a PhD in Experimental Medicine and another in Pharmaceutical Biotechnology and Clinical Pharmacology. With over 395 publications and more than 15,000 citations, she has an h-index of 62, reflecting her significant impact in the field. Her research interests include autoimmunity, acute and chronic inflammation, and signal pathway modulation, employing various analytical methodologies such as animal models, histology, and molecular biology techniques. Dr. Di Paola is actively involved in national and international research groups, holds editorial positions in various journals, and has received multiple awards for her scientific contributions.
Publication Profile
Scopus
Academic Credentials
Multiple PhDs: Holding a PhD in Experimental Medicine and another in Pharmaceutical Biotechnologies and Clinical Pharmacology, along with a specialization in Clinical Pathology, showcases her extensive academic background and expertise in biochemistry and pharmacology.
Research Focus
Innovative Areas: Dr. Di Paola’s research interests in autoimmunity, acute and chronic inflammation, and signal pathway modulation are critical areas in biomedical research, contributing to advancements in understanding various diseases and therapeutic approaches.
Conclusion
Prof. Dr. Rosanna Di Paola’s extensive publication record, innovative research focus, leadership in collaborative projects, and active role in the scientific community collectively make her an exceptional candidate for the Best Researcher Award. Her contributions not only advance academic knowledge but also have practical implications for health and medicine.
Publication Top Notes
- Hydrogen sulfide-releasing cyclooxygenase inhibitor ATB-346 enhances motor function and reduces cortical lesion volume following traumatic brain injury in mice. Journal of Neuroinflammation, 11(1), 196. 🔗 [10.1186/s12974-014-0196-1]
- Erratum: Retraction notice to “Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation.” European Journal of Pharmacology, 983, 177006. 🔗
- Investigation of neurochemical and behavioral alterations in the brain during fibromyalgia with supplementation of Spirulina platensis. Journal of Functional Foods, 121, 106387. 🔗
- Role of mitochondrial dysfunction and biogenesis in fibromyalgia syndrome: Molecular mechanism in central nervous system. Biochimica et Biophysica Acta – Molecular Basis of Disease, 1870(7), 167301. 🔗
- Assessing carnosinase 1 activity for diagnosing congenital disorders of glycosylation. Molecular Genetics and Metabolism, 143(1-2), 108571. 🔗
- Transgenerational hormesis in healthy aging and antiaging medicine from bench to clinics: Role of food components. Mechanisms of Ageing and Development, 220, 111960. 🔗
- Impaired mitochondrial quality control in fibromyalgia: Mechanisms involved in skeletal muscle alteration. Archives of Biochemistry and Biophysics, 758, 110083. 🔗
- Environmental endocrine disruptor risks in the central nervous system: Neurotoxic effects of PFOS and glyphosate. Environmental Toxicology and Pharmacology, 109, 104496. 🔗
- Erratum: Retraction Note: Glycogen synthase kinase-3β inhibition attenuates the development of ischaemia/reperfusion injury of the gut. Intensive Care Medicine, 50(6), 1019. 🔗
- Erratum: Retraction notice to “Glycogen synthase kinase-3β inhibition attenuates the degree of arthritis caused by type II collagen in the mouse.” Clinical Immunology, 262, 110198. 🔗